EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Tullia C Bruno, Anthony R Cillo iD

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Tullia C Bruno und 1 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Immune Checkpoint Inhibitors, T-Lymphocytes, Cytotoxic, Cellular Reprogramming. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination immunotherapies have entered the treatment armamentarium of oncology, but important knowledge gaps remain in our understanding of how these therapeutics work. A recent study by Rolig, Peng, and colleagues has shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. The authors first interrogated LAG3 expression on T cells across murine tumor models, classifying the models as LAG3 hi or LAG3 lo . Next, they found that LAG3 hi models were unresponsive to anti‐PD1 alone but responsive to combination therapy with anti‐PD1 + anti‐LAG3. Surprisingly, the response to anti‐PD1 + anti‐LAG3 in LAG3 hi models was associated with reprogramming of CD4 + regulatory T cells (Treg) from the canonically immunosuppressive state to an inflammatory state characterized by loss of expression of the transcription factor Foxp3 and upregulation of transcription factor Tbet. Importantly, an analogous reprogrammed Treg state was associated with response to anti‐PD1 + anti‐LAG3 and longer overall survival in patients with metastatic melanoma. This work highlights the importance of cells beyond cytotoxic CD8 + T cells as drivers of response to immunotherapy and sets the stage for subsequent mechanistic and translational studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryImmune Checkpoint InhibitorsT-Lymphocytes, CytotoxicCellular ReprogrammingAnimalsHumansMiceLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 ReceptorImmunotherapy

Stichwörter der Autor:innen

Treg fragilityTreg stabilitycancer immunologyimmunotherapyimmuno‐oncologyregulatory T cells

Substanzen

Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.
  • Cancer Immunology and Immunotherapy Program, University of Pittsburgh, PA, USA.
  • Department of Immunology, University of Pittsburgh, PA, USA.
  • Center for Systems Immunology, University of Pittsburgh, PA, USA.

ORCID-Profile: Anthony R Cillo

Zitieren

APA

Bruno, T. C., & Cillo, A. R. (2025). Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade. Molecular Oncology. https://doi.org/10.1002/1878-0261.70076

Vancouver

Bruno TC, Cillo AR. Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade. Molecular Oncology. 2025. doi:10.1002/1878-0261.70076

BibTeX
@article{Bruno2025,
  author = {Bruno, Tullia C and Cillo, Anthony R},
  title = {Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70076}
}
Kostenlos starten →